Zavain Dar - 03 Apr 2023 Form 4/A - Amendment Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
03 Apr 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
28 Apr 2023, 16:34:05 UTC
Date Of Original Report
05 Apr 2023
Previous filing
12 Jul 2022
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +1,996 +3.6% $0.000000 57,569 03 Apr 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 Includes a total of 35,008 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the original Form 4 filing.